SCOPUS 정보 검색 플랫폼

Volumn 1, Issue 2, 2006, Pages 100-103

Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib

Author keywords

Cutaneous side effects; EGFR inhibitor; Erlotinib; Folliculitis; NSCLC; Perionyxis

Indexed keywords

EID: 33746036428 PISSN: 17762596 EISSN: 1776260X Source Type: Journal
DOI: 10.1007/s11523-006-0013-6 Document Type: Article

Times cited : (3)

References (8)

1
- 3242720345
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
- Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
- (2004) N Engl J Med , vol.351 , Issue.4 , pp. 337-345
- Cunningham, D.¹ Humblet, Y.² Siena, S.³

2
- 0036139727
- Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
- Albanell J, Rojo F, Averbuch S et al (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1):110-124
- (2002) J Clin Oncol , vol.20 , Issue.1 , pp. 110-124
- Albanell, J.¹ Rojo, F.² Averbuch, S.³

3
- 21344462378
- Cutaneous side-effects of kinase inhibitors and blocking antibodies
- Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491-500
- (2005) Lancet Oncol , vol.6 , Issue.7 , pp. 491-500
- Robert, C.¹ Soria, J.C.² Spatz, A.³

4
- 0038306878
- Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
- Mascia F, Mariani V, Girolomoni G, Pastore S (2003) Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163(1):303-312
- (2003) Am J Pathol , vol.163 , Issue.1 , pp. 303-312
- Mascia, F.¹ Mariani, V.² Girolomoni, G.³ Pastore, S.⁴

5
- 24044500971
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
- Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425-1433
- (2005) Ann Oncol , vol.16 , Issue.9 , pp. 1425-1433
- Segaert, S.¹ Van Cutsem, E.²

6
- 20844448897
- HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
- Perez-Soler R, Delord JP, Halpern A et al (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5):345-356
- (2005) Oncologist , vol.10 , Issue.5 , pp. 345-356
- Perez-Soler, R.¹ Delord, J.P.² Halpern, A.³

7
- 24644513947
- Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?
- Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23(22):5235-5246
- (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5235-5246
- Perez-Soler, R.¹ Saltz, L.²

8
- 10844264628
- An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
- Amador ML, Oppenheimer D, Perea S et al (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64(24):9139-9143
- (2004) Cancer Res , vol.64 , Issue.24 , pp. 9139-9143
- Amador, M.L.¹ Oppenheimer, D.² Perea, S.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.